David Woods, PhD
Assistant Professor, Medicine-Medical Oncology

Photo
Graduate Schools :
  • MS, Old Dominion University (2010)
  • PhD, University of South Florida (2013)
Undergraduate School:
  • BS, Old Dominion University (VA) (2006)
Languages: English
Department: Medicine-Medical Oncology

Recognition & Awards

  • ISAC Marylou Ingram Scholar, International Society for Advancement of Cytometry (2020)

Research Interests

My research utilizes high-dimension, single cell, multi-omic approaches combined with data science as an approach to discover and characterize immunophenotypes associated with cancer patient outcomes in response to immunotherapies. I am interested in applying, adapting, and creating technologies, assays and analytical approaches to better understand the complexities of tumor-immune interactions with the goal of enhancing current and developing new immunotherapies. Link to “My Bibliography” at NCBI: https://goo.gl/YbuhFn Link to Google Scholar Citations Summary: https://goo.gl/t4bDtr

Publications

  • Khushalani NI, Vassallo M, Goldberg JD, Eroglu Z, Kim Y, Cao B, Ferguson R, Monson KR, Kirchhoff T, Amato CM, Burke P, Strange A, Monk E, Gibney GT, Kudchadkar R, Markowitz J, Brohl AS, Pavlick A, Richards A, Woods DM, Weber J. Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma. J Immunother Cancer. 2022 Nov;10(11). PubMed PMID: 36450385
  • Weber JS, Levinson BA, Laino AS, Pavlick AC, Woods DM. Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma. Melanoma Res. 2022 Oct 1;32(5):324-333. PubMed PMID: 35678233
  • Burke PE, Strange A, Monk E, Thompson B, Amato CM, Woods DM. PhenoComb: a discovery tool to assess complex phenotypes in high-dimensional single-cell datasets. Bioinformatics Advances. 2022; 2(1). doi: 10.1093/bioadv/vbac052.
  • Woods DM, Laino AS, Winters A, Alexandre J, Freeman D, Rao V, Adavani SS, Weber JS, Chattopadhyay PK. Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes. JCI Insight. 2020 Jun 4;5(11). PubMed PMID: 32369447
  • Yoshida T, Ichikawa J, Giuroiu I, Laino AS, Hao Y, Krogsgaard M, Vassallo M, Woods DM, Stephen Hodi F, Weber J. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. J Immunother Cancer. 2020 Apr;8(1). PubMed PMID: 32303612
  • Ichikawa J, Yoshida T, Isser A, Laino AS, Vassallo M, Woods D, Kim S, Oelke M, Jones K, Schneck JP, Weber JS. Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. Clin Cancer Res. 2020 Apr 2. [Epub ahead of print] PubMed PMID: 32241816
  • Laino AS, Woods D, Vassallo M, Qian X, Tang H, Wind-Rotolo M, Weber J. Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition. J Immunother Cancer. 2020 Jun;8(1). PubMed PMID: 32581042
  • Woods DM, Laino AS, Winters A, Alexandre J, Freeman D, Rao V, Adavani SS, Weber JS, Chattopadhyay PK. Nivolumab and ipilimumab are associated with distinct immune landscape changes and response-associated immunophenotypes. JCI Insight. 2020 Jun 4;5(11). PubMed PMID: 32369447
  • Ichikawa J, Yoshida T, Isser A, Laino AS, Vassallo M, Woods D, Kim S, Oelke M, Jones K, Schneck JP, Weber JS. Rapid Expansion of Highly Functional Antigen-Specific T Cells from Patients with Melanoma by Nanoscale Artificial Antigen-Presenting Cells. Clin Cancer Res. 2020 Jul 1;26(13):3384-3396. PubMed PMID: 32241816
  • Yoshida T, Ichikawa J, Giuroiu I, Laino AS, Hao Y, Krogsgaard M, Vassallo M, Woods DM, Stephen Hodi F, Weber J. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. J Immunother Cancer. 2020 Apr;8(1). PubMed PMID: 32303612
  • Yusko E, Vignali M, Wilson RK, Mardis ER, Hodi FS, Horak C, Chang H, Woods DM, Robins H, Weber J. Association of Tumor Microenvironment T-cell Repertoire and Mutational Load with Clinical Outcome after Sequential Checkpoint Blockade in Melanoma. Cancer Immunol Res. 2019 Mar;7(3):458-465. PubMed PMID: 30635271
  • Chattopadhyay PK, Winters AF, Lomas WE 3rd, Laino AS, Woods DM. High-Parameter Single-Cell Analysis. Annu Rev Anal Chem (Palo Alto Calif). 2019 Jun 12;12(1):411-430. PubMed PMID: 30699035
  • Laino AS, Betts BC, Veerapathran A, Dolgalev I, Sarnaik A, Quayle SN, Jones SS, Weber JS, Woods DM. HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics. J Immunother Cancer. 2019 Feb 6;7(1):33. PubMed PMID: 30728070
  • Briere D, Sudhakar N, Woods DM, Hallin J, Engstrom LD, Aranda R, Chiang H, Sodré AL, Olson P, Weber JS, Christensen JG. The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy. Cancer Immunol Immunother. 2018 Mar;67(3):381-392. PubMed PMID: 29124315
  • Woods DM, Ramakrishnan R, Laino AS, Berglund A, Walton K, Betts BC, Weber JS. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma. Clin Cancer Res. 2018 Dec 15;24(24):6236-6247. PubMed PMID: 30131384
  • Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun. 2017 Sep 19;8(1):592. PubMed PMID: 28928380
  • Woods DM, Woan KV, Cheng F, Sodré AL, Wang D, Wu Y, Wang Z, Chen J, Powers J, Pinilla-Ibarz J, Yu Y, Zhang Y, Wu X, Zheng X, Weber J, Hancock WW, Seto E, Villagra A, Yu XZ, Sotomayor EM. T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model. Blood. 2017 Jul 13;130(2):146-155. PubMed PMID: 28550044
  • Sahakian E, Powers JJ, Chen J, Deng SL, Cheng F, Distler A, Woods DM, Rock-Klotz J, Sodre AL, Youn JI, Woan KV, Villagra A, Gabrilovich D, Sotomayor EM, Pinilla-Ibarz J. Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function. Mol Immunol. 2015 Feb;63(2):579-85. PubMed PMID: 25155994
  • Woods DM, Sodré AL, Villagra A, Sarnaik A, Sotomayor EM, Weber J. HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade. Cancer Immunol Res. 2015 Dec;3(12):1375-85. PubMed PMID: 26297712
  • Woan KV, Lienlaf M, Perez-Villaroel P, Lee C, Cheng F, Knox T, Woods DM, Barrios K, Powers J, Sahakian E, Wang HW, Canales J, Marante D, Smalley KSM, Bergman J, Seto E, Kozikowski A, Pinilla-Ibarz J, Sarnaik A, Celis E, Weber J, Sotomayor EM, Villagra A. Targeting histone deacetylase 6 mediates a dual anti-melanoma effect: Enhanced antitumor immunity and impaired cell proliferation. Mol Oncol. 2015 Aug;9(7):1447-1457. PubMed PMID: 25957812
  • Cheng F, Lienlaf M, Wang HW, Perez-Villarroel P, Lee C, Woan K, Rock-Klotz J, Sahakian E, Woods D, Pinilla-Ibarz J, Kalin J, Tao J, Hancock W, Kozikowski A, Seto E, Villagra A, Sotomayor EM. A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs. J Immunol. 2014 Sep 15;193(6):2850-62. PubMed PMID: 25108026
  • Cheng F, Lienlaf M, Perez-Villarroel P, Wang HW, Lee C, Woan K, Woods D, Knox T, Bergman J, Pinilla-Ibarz J, Kozikowski A, Seto E, Sotomayor EM, Villagra A. Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells. Mol Immunol. 2014 Jul;60(1):44-53. PubMed PMID: 24747960
  • Woods DM, Woan K, Cheng F, Wang H, Perez-Villarroel P, Lee C, Lienlaf M, Atadja P, Seto E, Weber J, Sotomayor EM, Villagra A. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res. 2013 Oct;23(5):341-8. PubMed PMID: 23963286
View All (23 Total) View Less

Professional Memberships

  • American Association of Cancer Research (AACR), Member
  • American Association of Immunologists (AAI), Member
  • Society for Immunotherapy of Cancer (SITC), Member
  • International Society for Advancement of Cytometry (ISAC), Member
  • American Association for the Advancement of Science (AAAS), Member

Practice Locations

UCHealth University of Colorado Hospital (UCH)
12605 E. 16th Ave
Aurora, CO 80045
720-848-0000

Specialty Information

Specialties
  • Psychology
Public Speaking
Yes

General Information

Graduate Schools:
  • MS, Old Dominion University (2010)
  • PhD, University of South Florida (2013)
Undergraduate Schools:
  • BS, Old Dominion University (VA) (2006)
Languages: English
Department: Medicine-Medical Oncology
SOM Resources
CU Resources
Contact Us
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Campus Box C290
Aurora, CO 80045

Update My Profile
;